NYSE:AIM

Aim Immunotech Stock News

Healthcare > Biotechnology

Buy AIM

*Your capital is at risk

$0.732

-0.0947 (-11.46%)

At Close: Jun 03, 2026

Aimia: Trading Close To Net Cash + Marketable Securities With M&A Optionality

07:35pm, Sunday, 13'th Nov 2022

Aimia is trading approximately around its net cash plus marketable securities value. Applying punitive discounts to its private investments, Aimia's NAVPS is roughly 30% above where the stock is tradi

Aimia, Inc. (AIMFF) Q3 2022 Earnings Call Transcript

11:46am, Wednesday, 09'th Nov 2022

Aimia, Inc. (OTCPK:AIMFF) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Albert Matousek - Head, IR & Communications Phil Mittleman - CEO Michael Lehmann - President

AIM ImmunoTech to add board members, review executive salaries; highlights clinical advances in past year

10:01am, Wednesday, 09'th Nov 2022

AIM ImmunoTech Inc (NYSE:AIM) said it will add two directors to its board to bring diversity and additional biotechnology commercialization experience. AIM ImmunoTech also said its board compensation

AIM ImmunoTech's product candidate Ampligen granted FDA Orphan Drug Designation for treatment of Ebola

09:05am, Wednesday, 02'nd Nov 2022

AIM ImmunoTech Inc (NYSE:AIM) announced that its dsRNA product candidate Ampligen (rintatolimod) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatmen

AIM ImmunoTech backed by Delaware Court of Chancery's decision to deny activist group's takeover bid

09:11am, Monday, 31'st Oct 2022

AIM ImmunoTech Inc (NYSE:AIM) said the Delaware Court of Chancery has denied an activist investor's bid to put two nominees on its board during the November 3 annual meeting of shareholders. In its d

AIM ImmunoTech receives regulatory go-ahead for Phase 2 trial of investigational drug Ampligen for patients with post-COVID conditions

09:38am, Wednesday, 12'th Oct 2022

AIM ImmunoTech Inc (NYSE:AIM) told investors it expects to begin enrolling patients in the first quarter next year for a Phase 2 trial of its investigational drug Ampligen as a therapeutic for patient

AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

08:45am, Wednesday, 21'st Sep 2022

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra I

AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07:25am, Wednesday, 07'th Sep 2022

OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

07:30am, Tuesday, 06'th Sep 2022

OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut

AIM ImmunoTech says study partner Roswell Park begins patient enrollment in Ampligen and resistant melanoma phase 2 trial

09:08am, Tuesday, 30'th Aug 2022

AIM ImmunoTech Inc (NYSE:AIM) said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in its phase 2 study evaluating Ampligen (rintatolimo

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by